Payment overview · 2025
General Payments
$1,389.68
62 reported records · 18 companies
Healthcare provider profile · identity verified
Yun Sun, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1316913098
Verified facts
What the public records show
CMS Open Payments records show Yun Sun, M.D. received $1,389.68 in general payments during 2025 across 62 reported records.
Novo Nordisk Inc accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Levorphanol Tartrate, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nucynta as an associated drug or biological on 230 records involving 95 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nucynta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $262.72 | 18.9% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $201.07 | 14.5% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $184.24 | 13.3% | 5 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $169.52 | 12.2% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $101.73 | 7.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.66 | 6.5% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $55.54 | 4.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.76 | 3.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.70 | 3.8% | 3 | 2025 |
| Virtus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $39.14 | 2.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.77 | 2.5% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $31.73 | 2.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $30.55 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.44 | 1.4% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.85 | 1.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.60 | 1.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,389.68 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $226.20 | 10 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $184.24 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $177.85 | 7 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $169.52 | 9 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $101.73 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $55.54 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.48 | 6 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $52.70 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| LEVORPHANOL TARTRATE Normalized: levorphanol tartrate |
Drug | Virtus Pharmaceuticals LLC | $39.14 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.52 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $32.81 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Cardiac Ambulatory Monitor Normalized: hillrom cardiac ambulatory monitor |
Device | Baxter Healthcare | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.41 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.35 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.60 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.60 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LEVORPHANOL TARTRATE levorphanol tartrate |
2025 | Levorphanol Tartrate | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | Nucynta open payments reported associated product |
CMS Open Payments — General Payments 230 supporting records · 95 recipient NPIs · example record 1224105108 |
Nucynta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 538 | 90 |
| Gabapentin | Gabapentin | 388 | 85 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 364 | 70 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 298 | 69 |
| Oxycodone Hcl | Oxycodone Hcl | 256 | 51 |
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 218 | 43 |
| Amlodipine Besylate | Amlodipine Besylate | 174 | 56 |
| Omeprazole | Omeprazole | 152 | 46 |
| Baclofen | Baclofen | 144 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 43 |
| Ozempic | Semaglutide | 130 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 121 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 31 |
| Trazodone Hcl | Trazodone Hcl | 104 | 30 |
| Pregabalin | Pregabalin | 100 | 22 |
| Metformin Hcl | Metformin Hcl | 97 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 23 |
| Clonazepam | Clonazepam | 93 | 14 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 25 |
| Mounjaro | Tirzepatide | 87 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 84 | 19 |
| Allopurinol | Allopurinol | 77 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 27 |
| Tramadol Hcl | Tramadol Hcl | 72 | 16 |
| Meloxicam | Meloxicam | 70 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 66 | 20 |
| Topiramate | Topiramate | 66 | 18 |
| Lisinopril | Lisinopril | 64 | 25 |
| Promethazine Hcl | Promethazine Hcl | 62 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 19 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 47 | suppressed |
| Losartan Potassium | Losartan Potassium | 47 | 17 |
| Celecoxib | Celecoxib | 40 | 11 |
| Lorazepam | Lorazepam | 36 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Eliquis | Apixaban | 30 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 17 |
| Azithromycin | Azithromycin | 26 | 23 |
| Carvedilol | Carvedilol | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 14 |
| Morphine Sulfate | Morphine Sulfate | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 23 |
| Fluconazole | Fluconazole | 22 | 13 |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 14 |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Linzess | Linaclotide | 20 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 14 |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 18 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nucynta | Tapentadol Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Furosemide | Furosemide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Spironolactone | Spironolactone | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Levorphanol Tartrate | Levorphanol Tartrate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 12 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Ramelteon | Ramelteon | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Prednisone | Prednisone | 11 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,389.68 · 62 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, Belbuca, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Hillrom - Cardiac Ambulatory Monitor, INSPIRE, Korlym, LEVORPHANOL TARTRATE, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PURIFIED CORTROPHIN GEL, QULIPTA, Rybelsus, SHINGRIX, TONMYA, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Levorphanol Tartrate play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error